المؤلفون: Usmani S.Z., Oriol A., Karlin L., Cavo M., Rifkin R.M., Hayek F., Kirschner E., Bharany N., Overton L., Mannem S., Harroff A., Jain S., Roque T., McIntyre K., Yasencha C.K., Houck W., Schjesvold F., Yimer H.A., LeBlanc R., Takezako N., McCroskey R.D., Lim A.B.M., Suzuki K., Kosugi H., Grigoriadis G., Avivi I., Facon T., Jagannath S., Lonial S., Ghori R.U., Farooqui M.Z.H., Marinello P., San-Miguel J., Lim A., Walker T., Nicol A., Reece D., Elemary M., Boudreault Pedneault J.S., Attal M., Weisel K., Engelhardt M., Mackensen A., Quinn J., Cohen A., Magen-Nativ H., Benyamini N., Larocca A., Matsumoto M., Iida S., Ishikawa T., Kondo Y., Sunami K., Ando K., Teshima T., Chou T., Iwasaki H., Miki H., Matsumura I., Onishi Y., Izutsu K., Kizaki M., George A., Blacklock H., Simpson D., Waage A., Samoilova O., Nikitin E., Chagorova T., McDonald A., Patel M., Oriol Rocafiguera A., San Miguel Izquierdo J., Mateos M., Streetly M., Forsyth P., Jackson G., Jenkins S., Rifkin R., Yimer H., McCroskey R., Martincic D., Tarantolo S., Larson S., Faroun Y., Vaughn J., Baz R., Saylors G., Neppalli A., Raptis A., Fung H., Janosky M., Stevens D., Coleman M., Costa D., Cross S., Fanning S., Berges D.F., Harris T., Zackon I., Atanackovic D., Lee K., Oliff I., Lee W., Bensinger W., Lutzky J., Baron A.

مصطلحات الفهرس: pruritus/si [Side Effect], randomized controlled trial, rash/si [Side Effect], respiratory failure/si [Side Effect], rhabdomyolysis/si [Side Effect], sepsis/si [Side Effect], Stevens Johnson syndrome/si [Side Effect], survival analysis, systemic lupus erythematosus/si [Side Effect], toxic hepatitis/si [Side Effect], treatment duration, adrenal insufficiency/si [Side Effect], aged, anemia/si [Side Effect], article, backache/si [Side Effect], cardiopulmonary insufficiency/si [Side Effect], chromosome analysis, colitis/si [Side Effect], computer assisted tomography, constipation/si [Side Effect], controlled study, coughing/si [Side Effect], decreased appetite/si [Side Effect], dermatitis/si [Side Effect], diarrhea/si [Side Effect], disease exacerbation/si [Side Effect], drug efficacy, drug eruption/si [Side Effect], drug safety, drug withdrawal, dry skin/si [Side Effect], dyspnea/si [Side Effect], erythema/si [Side Effect], erythema multiforme/si [Side Effect], fatigue/si [Side Effect], female, fever/si [Side Effect], Food and Drug Administration, health care quality, heart arrest/si [Side Effect], heart failure/si [Side Effect], human, hypersensitivity/si [Side Effect], hyperthyroidism/si [Side Effect], hypokalemia/si [Side Effect], hypothyroidism/si [Side Effect], infusion related reaction/si [Side Effect], insomnia/si [Side Effect], insulin dependent diabetes mellitus/si [Side Effect], intestine ischemia/si [Side Effect], intestine perforation/si [Side Effect], kidney failure/si [Side Effect], low drug dose, lung embolism/si [Side Effect], major clinical study, male, mortality rate, multicenter study, multiple myeloma/dt [Drug Therapy], myasthenia gravis/si [Side Effect], myocarditis/si [Side Effect], nausea/si [Side Effect], neutropenia/si [Side Effect], nuclear magnetic resonance imaging, open study, overall survival, pancreatitis/si [Side Effect], peripheral edema/si [Side Effect], phase 3 clinical trial, pneumonia/si [Side Effect], positron emission tomography, priority journal, progression free survival, quality of life assessment, upper gastrointestinal bleeding/si [Side Effect], upper respiratory tract infection/si [Side Effect], vomiting/si [Side Effect], dexamethasone/ae [Adverse Drug Reaction], dexamethasone/ct [Clinical Trial], dexamethasone/cb [Drug Combination], dexamethasone/dt [Drug Therapy], dexamethasone/po [Oral Drug Administration], dexamethasone/pv [Special Situation for Pharmacovigilance], lenalidomide/ae [Adverse Drug Reaction], lenalidomide/ct [Clinical Trial], lenalidomide/cb [Drug Combination], lenalidomide/dt [Drug Therapy], lenalidomide/po [Oral Drug Administration], lenalidomide/pv [Special Situation for Pharmacovigilance], pembrolizumab/ae [Adverse Drug Reaction], pembrolizumab/ct [Clinical Trial], pembrolizumab/cb [Drug Combination], pembrolizumab/dt [Drug Therapy], pembrolizumab/iv [Intravenous Drug Administration], pembrolizumab/pv [Special Situation for Pharmacovigilance], Article

URL: Click here for full text options
LibKey Link

المؤلفون: Usmani S.Z., Oriol A., Karlin L., Cavo M., Rifkin R.M., Hayek F., Kirschner E., Bharany N., Overton L., Mannem S., Harroff A., Jain S., Roque T., McIntyre K., Yasencha C.K., Houck W., Schjesvold F., Yimer H.A., LeBlanc R., Takezako N., McCroskey R.D., Lim A.B.M., Suzuki K., Kosugi H., Grigoriadis G., Avivi I., Facon T., Jagannath S., Lonial S., Ghori R.U., Farooqui M.Z.H., Marinello P., San-Miguel J., Lim A., Walker T., Nicol A., Reece D., Elemary M., Boudreault Pedneault J.S., Attal M., Weisel K., Engelhardt M., Mackensen A., Quinn J., Cohen A., Magen-Nativ H., Benyamini N., Larocca A., Matsumoto M., Iida S., Ishikawa T., Kondo Y., Sunami K., Ando K., Teshima T., Chou T., Iwasaki H., Miki H., Matsumura I., Onishi Y., Izutsu K., Kizaki M., George A., Blacklock H., Simpson D., Waage A., Samoilova O., Nikitin E., Chagorova T., McDonald A., Patel M., Oriol Rocafiguera A., San Miguel Izquierdo J., Mateos M., Streetly M., Forsyth P., Jackson G., Jenkins S., Rifkin R., Yimer H., McCroskey R., Martincic D., Tarantolo S., Larson S., Faroun Y., Vaughn J., Baz R., Saylors G., Neppalli A., Raptis A., Fung H., Janosky M., Stevens D., Coleman M., Costa D., Cross S., Fanning S., Berges D.F., Harris T., Zackon I., Atanackovic D., Lee K., Oliff I., Lee W., Bensinger W., Lutzky J., Baron A.

مصطلحات الفهرس: pruritus/si [Side Effect], randomized controlled trial, rash/si [Side Effect], respiratory failure/si [Side Effect], rhabdomyolysis/si [Side Effect], sepsis/si [Side Effect], Stevens Johnson syndrome/si [Side Effect], survival analysis, systemic lupus erythematosus/si [Side Effect], toxic hepatitis/si [Side Effect], treatment duration, adrenal insufficiency/si [Side Effect], aged, anemia/si [Side Effect], article, backache/si [Side Effect], cardiopulmonary insufficiency/si [Side Effect], chromosome analysis, colitis/si [Side Effect], computer assisted tomography, constipation/si [Side Effect], controlled study, coughing/si [Side Effect], decreased appetite/si [Side Effect], dermatitis/si [Side Effect], diarrhea/si [Side Effect], disease exacerbation/si [Side Effect], drug efficacy, drug eruption/si [Side Effect], drug safety, drug withdrawal, dry skin/si [Side Effect], dyspnea/si [Side Effect], erythema/si [Side Effect], erythema multiforme/si [Side Effect], fatigue/si [Side Effect], female, fever/si [Side Effect], Food and Drug Administration, health care quality, heart arrest/si [Side Effect], heart failure/si [Side Effect], human, hypersensitivity/si [Side Effect], hyperthyroidism/si [Side Effect], hypokalemia/si [Side Effect], hypothyroidism/si [Side Effect], infusion related reaction/si [Side Effect], insomnia/si [Side Effect], insulin dependent diabetes mellitus/si [Side Effect], intestine ischemia/si [Side Effect], intestine perforation/si [Side Effect], kidney failure/si [Side Effect], low drug dose, lung embolism/si [Side Effect], major clinical study, male, mortality rate, multicenter study, multiple myeloma/dt [Drug Therapy], myasthenia gravis/si [Side Effect], myocarditis/si [Side Effect], nausea/si [Side Effect], neutropenia/si [Side Effect], nuclear magnetic resonance imaging, open study, overall survival, pancreatitis/si [Side Effect], peripheral edema/si [Side Effect], phase 3 clinical trial, pneumonia/si [Side Effect], positron emission tomography, priority journal, progression free survival, quality of life assessment, upper gastrointestinal bleeding/si [Side Effect], upper respiratory tract infection/si [Side Effect], vomiting/si [Side Effect], dexamethasone/ae [Adverse Drug Reaction], dexamethasone/ct [Clinical Trial], dexamethasone/cb [Drug Combination], dexamethasone/dt [Drug Therapy], dexamethasone/po [Oral Drug Administration], dexamethasone/pv [Special Situation for Pharmacovigilance], lenalidomide/ae [Adverse Drug Reaction], lenalidomide/ct [Clinical Trial], lenalidomide/cb [Drug Combination], lenalidomide/dt [Drug Therapy], lenalidomide/po [Oral Drug Administration], lenalidomide/pv [Special Situation for Pharmacovigilance], pembrolizumab/ae [Adverse Drug Reaction], pembrolizumab/ct [Clinical Trial], pembrolizumab/cb [Drug Combination], pembrolizumab/dt [Drug Therapy], pembrolizumab/iv [Intravenous Drug Administration], pembrolizumab/pv [Special Situation for Pharmacovigilance], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35895
LibKey Link

المؤلفون: Spencer A., Quach H., Prince H.M.

مصطلحات الفهرس: dexamethasone/dt [Drug Therapy], dexamethasone/po [Oral Drug Administration], lenalidomide/cb [Drug Combination], lenalidomide/dt [Drug Therapy], lenalidomide/po [Oral Drug Administration], melphalan/cb [Drug Combination], melphalan/dt [Drug Therapy], melphalan/po [Oral Drug Administration], prednisone/cb [Drug Combination], prednisone/dt [Drug Therapy], thalidomide/cb [Drug Combination], thalidomide/dt [Drug Therapy], thalidomide/po [Oral Drug Administration], maintenance therapy, aged, cancer combination chemotherapy, cancer survival, elderly care, human, multiple cycle treatment, multiple myeloma/dt [Drug Therapy], priority journal, review, salvage therapy, bortezomib/cb [Drug Combination], bortezomib/dt [Drug Therapy], bortezomib/iv [Intravenous Drug Administration], dexamethasone/cb [Drug Combination], Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/30418
Click here for full text options
LibKey Link

المؤلفون: Quach H., Spencer A., Kalff A.

مصطلحات الفهرس: stroma cell, autologous stem cell transplantation, cancer recurrence, cell cycle arrest, cytogenetics, drug efficacy, drug megadose, drug potentiation, drug safety, human, immunity, immunomodulation, infection/si [Side Effect], multiple myeloma/dt [Drug Therapy], multiple myeloma/di [Diagnosis], multiple myeloma/th [Therapy], neutropenia/si [Side Effect], phase 3 clinical trial (topic), priority journal, randomized controlled trial (topic), review, apoptosis, thrombocytopenia/si [Side Effect], treatment duration, treatment response, venous thromboembolism/si [Side Effect], bortezomib/cb [Drug Combination], bortezomib/dt [Drug Therapy], dexamethasone/ae [Adverse Drug Reaction], dexamethasone/ct [Clinical Trial], dexamethasone/cb [Drug Combination], dexamethasone/it [Drug Interaction], dexamethasone/dt [Drug Therapy], lenalidomide/ae [Adverse Drug Reaction], lenalidomide/ct [Clinical Trial], lenalidomide/cb [Drug Combination], lenalidomide/it [Drug Interaction], lenalidomide/dt [Drug Therapy], lenalidomide/po [Oral Drug Administration], lenalidomide/pd [Pharmacology], melphalan/ct [Clinical Trial], melphalan/cb [Drug Combination], melphalan/dt [Drug Therapy], pomalidomide/dt [Drug Therapy], prednisolone/ct [Clinical Trial], prednisolone/cb [Drug Combination], prednisolone/dt [Drug Therapy], prednisone/dt [Drug Therapy], thalidomide/dt [Drug Therapy], antineoplastic activity, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/28291
Click here for full text options
LibKey Link

المؤلفون: Quach H., Spencer A., Kalff A.

مصطلحات الفهرس: stroma cell, autologous stem cell transplantation, cancer recurrence, cell cycle arrest, cytogenetics, drug efficacy, drug megadose, drug potentiation, drug safety, human, immunity, immunomodulation, infection/si [Side Effect], multiple myeloma/dt [Drug Therapy], multiple myeloma/di [Diagnosis], multiple myeloma/th [Therapy], neutropenia/si [Side Effect], phase 3 clinical trial (topic), priority journal, randomized controlled trial (topic), review, apoptosis, thrombocytopenia/si [Side Effect], treatment duration, treatment response, venous thromboembolism/si [Side Effect], bortezomib/cb [Drug Combination], bortezomib/dt [Drug Therapy], dexamethasone/ae [Adverse Drug Reaction], dexamethasone/ct [Clinical Trial], dexamethasone/cb [Drug Combination], dexamethasone/it [Drug Interaction], dexamethasone/dt [Drug Therapy], lenalidomide/ae [Adverse Drug Reaction], lenalidomide/ct [Clinical Trial], lenalidomide/cb [Drug Combination], lenalidomide/it [Drug Interaction], lenalidomide/dt [Drug Therapy], lenalidomide/po [Oral Drug Administration], lenalidomide/pd [Pharmacology], melphalan/ct [Clinical Trial], melphalan/cb [Drug Combination], melphalan/dt [Drug Therapy], pomalidomide/dt [Drug Therapy], prednisolone/ct [Clinical Trial], prednisolone/cb [Drug Combination], prednisolone/dt [Drug Therapy], prednisone/dt [Drug Therapy], thalidomide/dt [Drug Therapy], antineoplastic activity, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/28291
LibKey Link

المؤلفون: Spencer A., Quach H., Prince H.M.

مصطلحات الفهرس: dexamethasone/dt [Drug Therapy], dexamethasone/po [Oral Drug Administration], lenalidomide/cb [Drug Combination], lenalidomide/dt [Drug Therapy], lenalidomide/po [Oral Drug Administration], melphalan/cb [Drug Combination], melphalan/dt [Drug Therapy], melphalan/po [Oral Drug Administration], prednisone/cb [Drug Combination], prednisone/dt [Drug Therapy], thalidomide/cb [Drug Combination], thalidomide/dt [Drug Therapy], thalidomide/po [Oral Drug Administration], maintenance therapy, aged, cancer combination chemotherapy, cancer survival, elderly care, human, multiple cycle treatment, multiple myeloma/dt [Drug Therapy], priority journal, review, salvage therapy, bortezomib/cb [Drug Combination], bortezomib/dt [Drug Therapy], bortezomib/iv [Intravenous Drug Administration], dexamethasone/cb [Drug Combination], Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/30418
LibKey Link